Glucagon like peptide-2 and neoplasia; a systematic review
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glucagon like peptide-2 and neoplasia; a systematic review. / Ring, Linea Landgrebe; Nerup, Nikolaj; Jeppesen, Palle Bekker; Svendsen, Lars Bo; Achiam, Michael Patrick.
In: Expert Review of Gastroenterology & Hepatology, Vol. 12, No. 3, 2018, p. 257-264.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon like peptide-2 and neoplasia; a systematic review
AU - Ring, Linea Landgrebe
AU - Nerup, Nikolaj
AU - Jeppesen, Palle Bekker
AU - Svendsen, Lars Bo
AU - Achiam, Michael Patrick
PY - 2018
Y1 - 2018
N2 - ntroduction: Glucagon like peptide-2 is synthesized from enteroendocrine L cells primarily located in the ileum and large intestine. GLP-2 stimulates crypt cell proliferation, increases intestinal blood flow, enhances gut barrier function, induces mucosal healing, and exerts an anti-apoptotic effect. Due to these effects GLP-2 is used in the treatment of short bowel syndrome (SBS).Areas covered: The aim of this systematic review was to provide information on the potential risk of intestinal neoplasia in patients receiving treatment with GLP-2. The literature search was performed independently by two authors in the following databases; Pubmed, Embase, Scopus, Web of Science and Cochrane.Expert commentary: This systematic review indicated that treatment with GLP-2(1–33) up to 30 months in humans without any known pre-existing cancer did not confer an increased risk of intestinal neoplasia in patients or animals. However, due to the small amount of patients studied it is premature to reach any final conclusions about GLP-2 – induced neoplasia. GLP-2(1–33) treatment in animals with a pre-induced cancer showed that GLP-2(1–33) may promote growth of existing neoplasia.
AB - ntroduction: Glucagon like peptide-2 is synthesized from enteroendocrine L cells primarily located in the ileum and large intestine. GLP-2 stimulates crypt cell proliferation, increases intestinal blood flow, enhances gut barrier function, induces mucosal healing, and exerts an anti-apoptotic effect. Due to these effects GLP-2 is used in the treatment of short bowel syndrome (SBS).Areas covered: The aim of this systematic review was to provide information on the potential risk of intestinal neoplasia in patients receiving treatment with GLP-2. The literature search was performed independently by two authors in the following databases; Pubmed, Embase, Scopus, Web of Science and Cochrane.Expert commentary: This systematic review indicated that treatment with GLP-2(1–33) up to 30 months in humans without any known pre-existing cancer did not confer an increased risk of intestinal neoplasia in patients or animals. However, due to the small amount of patients studied it is premature to reach any final conclusions about GLP-2 – induced neoplasia. GLP-2(1–33) treatment in animals with a pre-induced cancer showed that GLP-2(1–33) may promote growth of existing neoplasia.
KW - Cancer
KW - clinical
KW - glucagon like peptide-2
KW - glucagon like peptide-2 receptor
KW - intestinal failure
KW - neoplasia
KW - short bowel syndrome
KW - systematic review
KW - tedugluti
U2 - 10.1080/17474124.2018.1417032
DO - 10.1080/17474124.2018.1417032
M3 - Journal article
C2 - 29231791
VL - 12
SP - 257
EP - 264
JO - Expert Review of Gastroenterology & Hepatology
JF - Expert Review of Gastroenterology & Hepatology
SN - 1747-4124
IS - 3
ER -
ID: 191197199